ApprovalJul 14, 2026
FDA approval — Agilent Receives FDA Approval For The PD‑L1 LHC 28‑8 PharmDx Assay As Companion Diagnostic To Identify Patients With Ca…▸
high impact
Data −Jul 13, 2026
Negative data — Agilent (A): Buy, Sell, or Hold Post Q1 Earnings?▸
high impact
DealJul 06, 2026
Deal — Surplus Solutions, an NMS Capital Portfolio Company, Accelerates Technical Service Capabilities; Announces Partnership…▸
medium impact
ReadoutJul 01, 2026
Clinical data — Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight▸
medium impact
DealJun 25, 2026
Deal — Agilent (A) Stock Trades Up, Here Is Why▸
medium impact
DealJun 20, 2026
Deal — Agilent (A) Opens China Innovation Center And Buys Biocare For Cancer Diagnostics▸
medium impact
ApprovalJun 02, 2026
FDA approval — Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carc…▸
high impact
EarningsMay 20, 2026
Q2 2026 report+1.1%muted
DealMay 20, 2026
Deal — Agilent and Singapore's NATi Partner to Advance Lipid-Conjugated Oligonucleotide Research▸
medium impact
ApprovalMay 06, 2026
FDA approval — Assessing Agilent Technologies (A) Valuation After FDA Approval Of PD L1 Assay For KEYTRUDA▸
high impact
EarningsFeb 25, 2026
Q1 2026 report-5.3%negative
EarningsNov 24, 2025
FY 2025 report-0.1%muted
EarningsAug 27, 2025
Q3 2025 report+5.5%positive
EarningsMay 28, 2025
Q2 2025 report+0.1%muted
EarningsFeb 26, 2025
Q1 2025 report-6.1%negative
EarningsNov 25, 2024
FY 2024 report+2.6%muted
EarningsAug 21, 2024
Q3 2024 report+0.4%muted